primary membranous nephropathy
Stories
-
FDA approves first drug to treat adults with primary membranous nephropathy
The FDA approved Gazyva (obinutuzumab) injection for adults with primary membranous nephropathy at risk of disease progression to induce remission of proteinuria. In the MAJESTY Phase 3 study, 36% of patients achieved complete remission at week 104 versus 6% with tacrolimus.
-
Amgen registers Phase 3 study of inebilizumab in primary membranous nephropathy
This study was first posted on ClinicalTrials.gov on October 1, 2026. The study plans to enroll 159 participants and aims to evaluate the efficacy of inebilizumab on PMN disease activity as measured by complete remission.